FDA Steps Up Oversight Of Virtual Pharmaceutical Advertisements

FDA’s two complaints in the first two months of 2022 alone over inappropriate use of virtual marketing to promote drug products signal stakeholders could be right in expecting stepped up vigilance by FDA over drug makers’ growing use of social media and other forms of digital marketing to promote their products. After seeing hardly any FDA oversight of such advertising in 2021, drug industry stakeholders took notice when FDA in January complained to Eli Lilly and Company that its Instagram...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 

Pharma’s Digital Marketing Not Meeting Health Care Practitioners’ Needs

The COVID-19 pandemic forced pharmaceutical companies to adopt digital-first marketing models when in-person strategies were inaccessible, but health care practitioners report they’re becoming increasingly inundated with information and the shift to virtual marketing isn’t meeting their needs. Digital marketing channels for health care practitioners most commonly include webinars, social media outreach, emails and text messaging from representatives and self-directed web and remote detailing. While health care practitioners are becoming more familiar with digital technologies, the Digitally Savvy HCP , out...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Foundation: Health App Makers Can Hike Access With Thoughtful Design

The California Health Care Foundation released a report calling on developers of health apps and other digital products to do more to reach consumers who are uncomfortable with technology, non-native English speakers, or otherwise face barriers to access. “Digital health tools and approaches that are relevant for different lived experiences -- the information different groups need, how they like to receive information, and what appeals to them in a user interface -- will ultimately offer something that is more appealing,...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 




Biotech, Pharma Orgs: Medicine Should Be Exempt From Russia Sanctions

Members of the biotech and pharmaceutical industries recently spoke out against Russia’s invasion of Ukraine and urged their colleagues in the biotechnology and life sciences industries to immediately halt all business involvement in Russia, with the exception of trade in food and medicine, which they believe should continue. The call-to-action, which as of Tuesday (March 1) had amassed support from more than 500 physicians, manufacturers and investment firms, was posted one day after former FDA official Tim Coté petitioned the...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 03/04/2022
FDA Volume: 
Vol. 28, No. 9
Author: 

PBGH Expects More Arbitration, Higher Premiums Without IDR Guidance

Arbiters’ payment decisions are likely to vary widely in the short term due to federal District Judge Jeremy Kernodle’s decision to vacate pieces of the administration’s October interim final rule on surprise billing, but providers will eventually make their way to the most sympathetic independent dispute resolution entities and health care premiums are likely to increase in the long term, predicts a business group that supported the administration in the case. The Purchaser Business Group on Health (PGBH), which represents...
Overline: 
After district judge vacates pieces of the surprise billing rule . . .
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 03/10/2022
CMS Volume: 
Vol. 25, No. 10
HEA Issue: 
Health Exchange Alert Weekly Report - 03/09/2022
HEA Volume: 
Vol. 10, No. 10
Author: 

Biden Touts ACA, Mental Health, Nursing Home, Drug Pricing Policies In State Of The Union Address

President Joe Biden used his State of the Union speech Tuesday (March 1) to lay out his plans to tackle the mental health and opioid crises, as well as point to his administration’s intentions to strengthen nursing home oversight, tackle cancer and prepare for the next potential wave of COVID-19 . He also called for Democrats to pick back up on key pieces of their stalled social spending plan, chiefly proposals to extend the temporarily enhanced Affordable Care Act premium...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 03/04/2022
FDA Volume: 
Vol. 28, No. 9
CMS Issue: 
Inside CMS - 03/03/2022
CMS Volume: 
Vol. 25, No. 9
HEA Issue: 
Health Exchange Alert Weekly Report - 03/09/2022
HEA Volume: 
Vol. 10, No. 10
Author: 

WH ‘Test To Treat’ Program Aims To Speed Access To COVID Antivirals

The Biden administration this month will launch a so-called Test to Treat initiative through which people can get tested for coronavirus at a pharmacy and receive antiviral pills on the spot, at no cost to patients, President Joe Biden announced Tuesday evening (March 1) during his first State of the Union address. The initiative also will allow antiviral pills to be distributed directly to long-term care facilities, a White House official said. The administration also will send out more free...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 03/04/2022
FDA Volume: 
Vol. 28, No. 9
Author: 

Pages

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.